The Committee for Veterinary Medicinal Products (CVMP) convened in Amsterdam from April 8-9, 2025, to deliberate on various veterinary medicinal products. The meeting, held in person, saw the adoption of multiple opinions and assessment reports, particularly focusing on innovative vaccines for poultry and companion animals. Key decisions included the endorsement of new vaccines aimed at combating avian infectious bronchitis and Newcastle disease in chickens, as well as medications addressing nausea and vomiting in dogs.
Key Approvals and Recommendations
Among the significant approvals, the CVMP endorsed the Nobilis Multriva IBm+ND vaccine for chickens, targeting respiratory issues caused by specific strains of infectious bronchitis virus and Newcastle disease virus. Additionally, the committee approved Emevet, a maropitant-based medication for dogs, designed to prevent chemotherapy-induced nausea and motion sickness-related vomiting. These approvals reflect the CVMP’s commitment to enhancing animal health through effective medicinal solutions.
Committee Procedures and Future Initiatives
The meeting also addressed procedural aspects, including the adoption of the previous meeting’s minutes without amendments and the handling of competing interests among committee members. The CVMP emphasized transparency and adherence to the Agency’s policies on document access and confidentiality. Furthermore, the committee discussed upcoming events and strategic initiatives, such as the Veterinary Medicine Safety Day campaign and the joint EU medicines agencies’ network strategy to 2028, aiming to tackle public health challenges like antimicrobial resistance.
- The approval of Nobilis Multriva IBm+ND marks a significant advancement in poultry disease prevention.
- Emevet’s endorsement highlights progress in managing chemotherapy side effects in veterinary medicine.
- Strategic initiatives indicate a proactive approach towards combating antimicrobial resistance.
The CVMP’s decisions during the April meeting underscore its pivotal role in regulating and approving veterinary medicinal products within the European Union. By focusing on both preventive measures through vaccines and therapeutic solutions for companion animals, the committee ensures comprehensive animal health management.
Looking ahead, stakeholders in the veterinary pharmaceutical industry can anticipate further guidance and support from the CVMP, especially in areas concerning public health threats and innovative medicinal technologies. The committee’s strategic initiatives and upcoming campaigns are poised to shape the future landscape of veterinary medicine, promoting healthier livestock and pets across the EU.
Veterinarians, farmers, and pet owners alike stand to benefit from the CVMP’s continued efforts to enhance animal health standards. The committee’s meticulous evaluation process and commitment to transparency ensure that approved products meet stringent safety and efficacy criteria, fostering trust and reliability in veterinary medicinal products.
In summary, the April 2025 CVMP meeting yielded crucial approvals for new veterinary vaccines and medications, reinforced procedural integrity, and outlined strategic initiatives aimed at addressing current and future challenges in animal health management. These actions collectively contribute to the overarching goal of safeguarding animal welfare and public health within the European Union.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
